New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
10:00 EDTACPW, USPH, KING, TCB, RNDY, RNG, REGN, PCYC, IRT, ICLR, GILD, CIG, CELG, BIIB, ASBC, AMGN, COMMOn The Fly: Analyst Initiation Summary
Active Power (ACPW) initiated with a Buy at Roth Capital... Amgen (AMGN) initiated with an Overweight at Morgan Stanley... Associated Banc-Corp (ASBC) initiated with a Neutral at DA Davidson... Biogen (BIIB) initiated with an Overweight at Morgan Stanley... Celgene (CELG) initiated with an Equal Weight at Morgan Stanley... Cemig (CIG) initiated with a Buy at Goldman... Gilead (GILD) initiated with an Equal Weight at Morgan Stanley... ICON plc (ICLR) initiated with an Outperform at Credit Suisse... Independence Realty Trust (IRT) initiated with a Buy at Deutsche Bank... Pharmacyclics (PCYC) initiated with an Equal Weight at Morgan Stanley... Regeneron (REGN) initiated with an Equal Weight at Morgan Stanley... RingCentral (RNG) initiated with an Outperform at Macquarie... Roundy's (RNDY) initiated with a Buy at BofA/Merrill... TCF Financial (TCB) initiated with a Neutral at DA Davidson... King Digital (KING) initiated with a Neutral at Sterne Ageel... U.S. Physical Therapy (USPH) initiated with an Overweight at Stephensl... CommScope (COMM) initiated with a Buy at Longbow.
News For ACPW;AMGN;ASBC;BIIB;CELG;CIG;GILD;ICLR;IRT;PCYC;REGN;RNG;RNDY;TCB;KING;USPH;COMM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 10, 2014
08:41 EDTCELGCelgene reports apremilast significantly improved preexisting psoriasis in study
Subscribe for More Information
08:39 EDTCELGCelgene says data show Apremilast treatment resulted in improved quality of life
Subscribe for More Information
08:19 EDTGILDMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
07:50 EDTICLRICON plc downgraded to Neutral from Buy at ISI Group
As previously reported, ISI Group downgraded ICON plc to Neutral from Buy. The firm downgraded shares based on valuation and lack of near-term catalysts. Price target is $62.
07:21 EDTGILDFDA PDUFA Date for Gilead Sciences Sofosbuvir is October 10, 2014
Subscribe for More Information
06:19 EDTICLRICON plc downgraded to Neutral from Buy at ISI Group
October 9, 2014
16:11 EDTAMGNAmgen blinatumomab granted priority review by FDA
Subscribe for More Information
11:43 EDTGILDStocks with call strike movement; GILD EWZ
Gilead (GILD) February 120 call option implied volatility increased 3% to 38, MSCI Brazil Index (EWZ) February 58 call option implied volatility increased 3% to 38 according to IVolatility.
10:00 EDTRNGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:28 EDTGILDGilead to be challenged by AbbVie in HCV near-term, says Bernstein
Subscribe for More Information
05:27 EDTRNGRingCentral downgraded to Neutral from Buy at Goldman
Subscribe for More Information
October 8, 2014
16:26 EDTGILDOn The Fly: Closing Wrap
Subscribe for More Information
16:01 EDTGILDOptions Update; October 8, 2014
iPath S&P 500 VIX Short-Term Futures down 2.73 to 29.51. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX PBR AA CLF GILD according to Track Data.
15:49 EDTGILDAchillion, Gilead rise after late breaking abstract for AASLD posted
Shares of Achillion (ACHN) are higher after the company announced this morning that four abstracts have been accepted for presentation at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases. Among those four is a late breaker poster presentation providing updated results, including SVR12, from an ongoing Phase 2 proxy study evaluating Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-na´ve genotype 1 chronic hepatitis C virus infection. Sofosbuvir is sold under the brand name Sovaldi by Gilead Sciences (GILD). In a note to investors, FBR Capital noted that the "surprise" late-breaking poster for the meeting showed a 100% cure rate for the combination therapy. In late afternoon trading, Achillion shares are up 10% to $10.74 while Gilead is up 4.3% to $108.78.
10:48 EDTKINGGlu drops despite Benchmark optimism about Kardashian game
Research firm Benchmark Co. upgraded digital video game maker Glu Mobile (GLUU) to Buy from Hold, based on optimism about the company's upcoming third quarter earnings report. WHAT'S NEW: Glu may report higher than expected third quarter sales and earnings before interest taxes depreciation and amortization on October 29, Benchmark analyst Mike Hickey wrote in a note to investors today. The company may also raise its fourth quarter guidance, Hickey believes. Glu's results are being lifted by the success of the company's "Kim Kardashian: Hollywood" game, the analyst believes. He has a $5.90 price target on the name. WHAT'S NOTABLE: Taking the opposite view on Glu Mobile in an article yesterday was a short-selling blog, TheStreetSweeper. The blog said it "wouldn't be surprised" if the company cut its Q4 guidance, as Kim Kardashian and other Glu games "are fading fast." Company insiders are "selling huge chinks" of the company's shares, added the blog. Northland Capital analyst Darren Aftahi yesterday countered by accusing TheStreetSweeper of "acting as a megaphone" for shorts in the name, trying to drive down the stock in a weak market, and producing an article that is "full of conjecture." The analyst said he thinks the company could beat Q3 revenue expectations by a large amount, potentially producing a "massive short squeeze." OTHERS TO WATCH: Other digital video game makers include Zynga (ZNGA) and King Digital (KING). PRICE ACTION: In early trading, Glu dropped 4% to $4.56.
10:20 EDTAMGNAmgen biosimilar franchise underappreciated, says Piper Jaffray
After Amgen announced positive Phase 3 results for its biosimilar Humira in psoriasis, Piper Jaffray said it believes that Amgen's overall pipeline is underappreciated since the company's biosimilar franchise is generally not included in consensus estimates. The firm views Amgen as a top large cap picks and reiterate its Overweight rating on the stock.
09:16 EDTAMGNAmgen's ABP 501 for psoriasis shows positive Phase 3 results
Subscribe for More Information
07:19 EDTAMGNCBI to hold a conference
Subscribe for More Information
07:18 EDTGILDInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
07:11 EDTCELG, AMGNEuropean Academy of Dermatology and Venereology to hold a conference
23rd EADV Congress is being held in Amsterdam, The Netherlands on October 8-12.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use